Table 3.
Short and long-term outcomes post-TAVR
| Outcomesa | All Subjects (n = 610) | Non- XRT Group (n = 535) | C-XRT Group (n = 75) | P value |
|---|---|---|---|---|
| Early Events | ||||
| ICU LOS (hrs) | 41.9 ± 43.1 | 41.50 ± 43.19 | 44.67 ± 43.00 | 0.55 |
| Hospital LOS (days) | 5.2 ± 6.5 | 5.32 ± 6.84 | 4.52 ± 3.64 | 0.31 |
| In Hospital AMI | 1 (0.16) | 1 (0.19) | 0 (0) | 1.0 |
| In Hospital AF | 49 (8.03) | 13 (2.43) | 36 (48.00) | < 0.0001 |
| In Hospital stroke | 9 (1.48) | 5 (0.93) | 4 (5.33) | 0.01 |
| In Hospital cardiac arrest | 20 (3.28) | 15 (2.80) | 5 (6.67) | 0.08 |
| In Hospital Mortality | 17 (2.79) | 12 (2.24) | 5 (6.67) | 0.04 |
| 30-day Mortality | 17 (2.79) | 12 (2.24) | 5 (6.67) | 0.04 |
| Major bleed | 63 (10.33) | 52 (9.72) | 11 (14.67) | 0.22 |
| Long-term Events | ||||
| AMI and/or urgent PCI | 35 (5.74) | 31 (5.79) | 4 (5.33) | 1.00 |
| Stroke/TIA | 36 (5.90) | 27 (5.05) | 9 (12.00) | 0.03 |
| HF admission | 113 (18.52) | 90 (16.82) | 23 (30.67) | 0.006 |
| PPM implants | 64 (10.49) | 49 (9.16) | 15 (20.0) | 0.007 |
| CV Mortality | 50 (48.54) | 36 (44.44) | 14 (63.64) | 0.14 |
| All-Cause Mortality | 103 (16.89) | 81 (15.14) | 22 (29.33) | 0.004 |
| MACE | 185 (30.33) | 144 (26.92) | 41 (54.67) | < 0.0001 |
| Quality of Life measures | ||||
| Home Disposition post TAVR | 513 (84.10) | 451 (84.30) | 62 (82.67) | 0.73 |
| KCCQ12 at 30 days | 79.23 ± 17.11 | 79.27 ± 16.98 | 78.96 ± 18.20 | 0.88 |
| KCCQ12 at 1 year | 83.02 ± 13.47 | 82.86 ± 13.55 | 84.29 ± 12.81 | 0.44 |
C-XRT indicates mediastinal radiation therapy
ICU intensive care unit, LOS length of stay, AF atrial Fibrillation, AMI acute myocardial infarction, PCI percutaneous coronary intervention, TIA transient ischemic attack, HF heart failure, PPM permanent pacemaker, CV cardiovascular, MACE major cardiovascular adverse event (CV death/MI/Stroke/HF), KCCQ12 Kansas City Cardiomyopathy Questionnaire
aValues are expressed as number (percentage) or mean ± SD